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OBJECTIVES: To determine the efficacy of a simple, short-term and low-cost eradication treatment for Helicobacter
pylori (H. pylori) using omeprazole, tetracycline, and furazolidone in a Brazilian peptic ulcer population, divided into 2
subgroups: untreated and previously treated for the infection.
PATIENTS AND METHODS: Patients with peptic ulcer disease diagnosed by endoscopic examination and infected
by H. pylori diagnosed by the rapid urease test (RUT) and histological examination, untreated and previously unsuccessfully
treated by macrolides and nitroimidazole, were medicated with omeprazole 20 mg daily dose and tetracycline 500 mg and
furazolidone 200 mg given 3 times a day for 7 days. Another endoscopy or a breath test was performed 12 weeks after the end
of treatment. Patients were considered cured of the infection if a RUT and histologic examination proved negative or a
breath test was negative for the bacterium.
RESULTS: Sixty-four patients were included in the study. The women were the predominant sex (58%); the mean age
was 46 years. Thirty-three percent of the patients were tobacco users, and duodenal ulcer was identified in 80% of patients.
For the 59 patients that underwent follow-up examinations, eradication was verified in 44 (75%). The eradication rate for the
intention-to-treat group was 69%. The incidence of severe adverse effects was 15%.
CONCLUSION: The treatment provides good efficacy for H. pylori eradication in patients who were previously
treated without success, but it causes severe adverse effects that prevented adequate use of the medications in 15% of the
patients.
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INTRODUCTION
The eradication of H. pylori in pa-
tients with peptic ulcer disease linked
to such bacterium cures the disease1,2.
At present, the treatments for H. pylori
eradication consist of the association of
2 antibiotics with an acid supressor3-5.
Clarithromycin and amoxicillin with a
proton pump inhibitor or clarithro-
mycin with or without amoxicillin and
bismuth-ranitidine provide high eradi-
cation rates in Brazil6,7. For the patients
in whom the bacterium cannot be eradi-
cated, considering the high prevalence
of primary resistance to nitroimidazoles
in our country8 and the expected sec-
ondary resistance to macrolides 9, the
furazolidone option10,11 is attractive,
due to its low cost and high efficacy,
and it has been proposed as the first or
second choice of treatment12-22.
The aim of this study was to test the
efficacy of a treatment schedule that
uses furazolidone with tetracycline and
omeprazole for 7 days in untreated pep-
tic ulcer patients and in those previ-
ously treated without success using
nitroimidazoles and macrolides.
PATIENTS AND METHODS
Patients with a diagnosis of scarred
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or active gastric or duodenal peptic ul-
cer disease, confirmed by upper diges-
tive endoscopy, performed at the Gas-
troenterology Unit of São Paulo Uni-
versity Medical School Hospital, and
infected by H. pylori were invited to
participate in the study. Patients un-
treated for H. pylori infection or pre-
viously treated without success for the
infection with nitroimidazoles and
macrolides were included in the study.
Patients with prior antibiotic therapy
up to 3 months prior to the study start
date, patients under 14 years old, pa-
tients with severe disease, pregnant or
lactating patients, and patients with
prior gastric surgery were excluded.
The Hospital Committee on Ethics
and Science approved the study, and
all patients signed the informed con-
sent statement.
Infection diagnosis:
Diagnosis of H. pylori infection
was made by histologic examination
in all cases, (H & E staining), and the
rapid urease test (RUT)23 was performed
on mucosal biopsy specimens of the
gastric antrum that were obtained
through upper digestive endoscopy.
Treatment:
Treatment consisted of tetracycline
500 mg and furazolidone 200 mg ad-
ministered 3 times a day after each
meal, with omeprazole 20 mg once a
day before breakfast, for 7 days. At end
of the treatment, patients were required
to avoid all anti-ulcer medications, ex-
cept for the symptomatic use of antacid
pills. Patients were then questioned
about the occurrence and intensity of
adverse effects, and the remaining pills
were counted.
Treatment assessment:
H. pylori infection was considered
cured if TRU and the histologic exami-
nation by upper endoscopy performed
12 weeks after the end of treatment
proved to be negative or a 14C-urea
breath test24 performed 12 weeks after
the end of treatment was negative.
 Statistical determinations were
made by SPSS, software package ver-
sion 8.0 (SPSS Inc. USA).
RESULTS
The clinical data of the studied
population are shown in table 1. The
female sex was predominant, and the
percentage of duodenal ulcer was high.
The mean age was similar to the me-
dian age. Smokers made up one third
of the total patient number. Five pa-
tients did not show up for follow-up
examinations. The eradication rates
were good: 75% for the per protocol
group (Table 2). The differences re-
garding eradication rates between the
previously treated group (77%) and the
previously untreated group (74%) did
not reach statistical significance (P =
0.71).
Adverse effects were reported by
34% of patients: 14% were of mild in-
tensity and 5% moderate intensity. Se-
vere adverse effects, mainly nausea and
vomiting episodes, were reported by
15% of the patients.
DISCUSSION
Even though it is possible to effec-
tively treat the symptoms of peptic ul-
cer disease using acid suppressors,
treatment with antibiotics25 is more
cost effective. Additionally, for com-
plicated ulcers, the latter treatment
also reduces risk of bleeding ulcers,
stenosis ulcers, perforating ulcers,
etc.26,27. Therefore, even when consid-
ering the greater difficulty in treating
resistant H. pylori infection (the re-
treatment schedules are more com-
plex, have lower efficacy, higher costs,
and more frequent adverse effects28,29),
it is important to seek effective treat-
ment schedules for such cases. A high
rate of primary resistance of H. pylori
to nitroimidazole compounds8 and re-
cently also amoxicillin9 has been de-
scribed in our country. The low cost
and simplicity of this treatment sched-
ule are very important attributes for the
eradication of H. pylori, if one consid-
ers the low cultural and social status
and the low income of the majority of
the Brazilian people. The choice of the
treatment schedule with tetracycline,
furazolidone, and omeprazole in-
volved consideration of these issues.
The eradication rate obtained for pre-
viously treated patients, which did not
differ from that of untreated patients,
can be considered satisfactory for a re-
treatment schedule.
The high incidence of adverse ef-
fects, also observed by another au-
thor14, is a noteworthy outcome of this
study, especially considering the se-
verity of the adverse effects. The treat-
ment schedule with clarithromycin,
tinidazole, and proton pump inhibi-
Table 1 - Clinical data of patients.
Patients 64
Age (years) Mean 46
Median 44







Table 2 -  Eradication rates.
n / % Confidence Interval (95%)
Per protocol 44/59(75%) 63% - 86%
Intention to treat 44/64 (69%) 57% - 80%
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tor30 resulted in 18% adverse effects,
and only 1 patient discontinued the
medications. This fact was a possible
limitation for the achievement of bet-
ter eradication rates. Adverse effects
are more frequently related to furazo-
lidone use14, a main drug of the treat-
ment schedule in our study. The addi-
tion of another drug to prevent adverse
effects, if possible, will change this
schedule into a new complex one.
Nevertheless, this treatment does not
promote secondary bacterial resistance
to the antibiotics31, and it is a short-
term and low-cost treatment; therefore,
it is an interesting option for a great
number of Brazilian patients with pep-
tic ulcers due to H. pylori infection,
particularly those who have antibiotic-
resistant infection.
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OBJETIVO: Testar a eficácia de
um esquema simplificado e de baixo
custo para erradicação do H. pylori uti-
lizando omeprazol, tetraciclina e
furazolidona, em uma população de
ulcerosos do Brasil, já tratados e não
tratados previamente para a infecção.
PACIENTES E MÉTODOS: Paci-
entes portadores de úlcera péptica, do-
cumentada por exame endoscópico e
infectados pelo H. pylori confirmado
pelo teste da urease e exame histológico,
não tratados previamente ou já tratados
sem sucesso com macrolídeos e nitro-
imidazólicos, foram tratados com
Omeprazol 20mg em dose única diária,
associado à Tetraciclina 500mg e
Furazolidona 200mg dadas três vezes ao
dia, por três dias. Uma nova endoscopia
ou um Teste Respiratório foi realizado
12 semanas após o término do tratamento
e foram considerados erradicados da in-
fecção os pacientes que apresentaram o
teste da urease e exame histológico ne-
gativos ou o Teste Respiratório negati-
vo para a bactéria.
RESULTADOS: Sessenta e quatro
pacientes foram incluídos no estudo, 26
deles não previamente tratados. As mu-
lheres predominaram (58%), a idade mé-
dia foi de 46 anos, 33% dos pacientes
eram tabagistas e a úlcera duodenal foi
identificada em 80% dos pacientes. Nos
59 doentes que realizaram o exame de
controle, a erradicação foi constatada
em 44 (75%). Por intenção de tratamen-
to o índice foi de 68%. O grupo não tra-
tado previamente não diferiu do grupo
previamente tratado. A incidência de
efeitos adversos intensos foi de 15%.
CONCLUSÃO: O esquema propor-
ciona boa eficácia na erradicação do
H. pylori em pacientes já previamente
tratados sem sucesso, porém apresenta
efeitos adversos intensos, que impediu




Erradicação. Tetraciclina.  Furazo-
lidona.  Omeprazol.
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